Research Article

Biodistribution of PLGA and PLGA/chitosan nanoparticles after repeat-dose oral delivery in F344 rats for 7 days

Sara M Navarro

Biological & Agricultural Engineering Department, LSU & LSU AgCenter, Baton Rouge, LA, USA

Search for more papers by this author

Caleb Darensbourg

Biological & Agricultural Engineering Department, LSU & LSU AgCenter, Baton Rouge, LA, USA

Search for more papers by this author

Linda Cross

Biological & Agricultural Engineering Department, LSU & LSU AgCenter, Baton Rouge, LA, USA

Search for more papers by this author

Rhett Stout

Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USA

Search for more papers by this author

Diana Coulon

LSU AgCenter

Search for more papers by this author

Carlos E Astete

Biological & Agricultural Engineering Department, LSU & LSU AgCenter, Baton Rouge, LA, USA

Search for more papers by this author

Timothy Morgan

Pathobiology & Population Medicine, College of Veterinary Medicine, Mississippi State University, MS, USA

Search for more papers by this author

Cristina M Sabliov

*Author for correspondence:

E-mail Address: csabliov@agcenter.lsu.edu

Biological & Agricultural Engineering Department, LSU & LSU AgCenter, Baton Rouge, LA, USA

Search for more papers by this author

Published Online:10 Dec 2014https://doi.org/10.4155/tde.14.79

View article

Abstract

Aim: To quantify in vivo the biodistribution of poly(lactic-co-glycolic) acid (PLGA) and PLGA/chitosan nanoparticles (PLGA/Chi NPs) and assess if the positive charge of chitosan significantly enhances nanoparticle absorption in the GI tract. Material & methods: PLGA and PLGA/Chi NPs covalently linked to tetramethylrhodamine-5-isothiocyanate (TRITC) were orally administered to F344 rats for 7 days, and the biodistribution of fluorescent NPs was analyzed in different organs. Results: The highest amount of particles (% total dose/g) was detected for both treatments in the spleen, followed by intestine and kidney, and then by liver, lung, heart and brain, with no significant difference between PLGA and PLGA/Chi NPs. Conclusion: Only a small percentage of orally delivered NPs was detected in the analyzed organs. The positive charge conferred by chitosan was not sufficient to improve the absorption of the PLGA/Chi NPs over that of PLGA NPs.

References

1 Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20(2–3), 153–214 (2003).Crossref, Medline, CAS, Google Scholar
2 Thompson CJ, Tetley L, Cheng WP. The influence of polymer architecture on the protective effect of novel comb shaped amphiphilic poly(allylamine) against in vitro enzymatic degradation of insulin – towards oral insulin delivery. Int. J. Pharm. 383(1–2), 216–227 (2010).Crossref, Medline, CAS, Google Scholar
3 Shen WC. Oral peptide and protein delivery: unfulfilled promises? Drug Discov. Today 8(14), 607–608 (2003).Crossref, Medline, Google Scholar
4 Yin YS, Chen DW, Qiao MX, Wei XY, Hu HY. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: Ex vivo bioadhesion and in vivo biodistribution. J. Control. Release 123(1), 27–38 (2007).Crossref, Medline, CAS, Google Scholar
5 Dai JD, Nagai T, Wang XQ et al. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. 280(1–2), 229–240 (2004).Crossref, Medline, CAS, Google Scholar
6 Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21(23), 2475–2490 (2000).Crossref, Medline, CAS, Google Scholar
7 Danhier F, Ansorena E, Silva JM et al. PLGA-based nanoparticles: An overview of biomedical applications. J. Control. Release 161(2), 505–522 (2012).Crossref, Medline, CAS, Google Scholar
8 Smith J, Wood E, Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 21(1), 43–49 (2004).Crossref, Medline, CAS, Google Scholar
9 Mohanraj VJ, Chen Y. Nanoparticles - A review. Trop. J. Pharm. Res. 5(1), 561–573 (2006).Google Scholar
10 Primard C, Rochereau N, Luciani E et al. Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. Biomaterials 31(23), 6060–6068 (2010).Crossref, Medline, CAS, Google Scholar
11 Sharma G, Van Der Walle CF, Kumar MNVR. Antacid co-encapsulated polyester nanoparticles for peroral delivery of insulin: Development, pharmacokinetics, biodistribution and pharmacodynamics. Int. J. Pharm. 440(1), 99–110 (2013).Crossref, Medline, CAS, Google Scholar
12 Peetla C, Labhasetwar V. Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir 25(4), 2369–2377 (2009).Crossref, Medline, CAS, Google Scholar
13 Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. Chem. Pharm. Bull. 58(11), 1423–1430 (2010).Crossref, Medline, CAS, Google Scholar
14 Plapied L, Duhem N, Des Rieux A, Preat V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface Sci. 16(3), 228–237 (2011).Crossref, CAS, Google Scholar
15 Leray AM, Vert M, Gautier JC, Benoit JP. Fate of [C-14] Poly(Dl-Lactide-Co-Glycolide) nanoparticles after intravenous and oral-administration to mice. Int. J. Pharm. 106(3), 201–211 (1994).Crossref, CAS, Google Scholar
16 Sonaje K, Lin KJ, Wey SP et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 31(26), 6849–6858 (2010).Crossref, Medline, CAS, Google Scholar
17 Semete B, Booysen LIJ, Kalombo L et al. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol. Appl. Pharmacol. 249(2), 158–165 (2010).Crossref, Medline, CAS, Google Scholar
18 Esmaeili F, Ghahremani MH, Esmaeili B et al. PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int. J. Pharm. 349(1–2), 249–255 (2008).Crossref, Medline, CAS, Google Scholar
19 Semete B, Booysen L, Kalombo L et al. Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration. Int. J. Pharm. 424(1–2), 115–120 (2012).Crossref, Medline, CAS, Google Scholar
20 Simon L, Sabliov C. Time analysis of poly(lactic-co-glycolic) acid nanoparticle uptake by major organs following acute intravenous and oral administration in mice and rats Ind. Biotechnol. 9(1), 19–23 (2013).Crossref, CAS, Google Scholar
21 Basu S, Harfouche R, Soni S et al. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc. Natl Acad. Sci. USA 106(19), 7957–7961 (2009).Crossref, Medline, CAS, Google Scholar
22 Carpino LA, Elfaham A, Albericio F. Efficiency in peptide coupling - 1-hydroxy-7-azabenzotriazole vs 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine. J. Org. Chem. 60(11), 3561–3564 (1995).Crossref, CAS, Google Scholar
23 Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17(3), 247–289 (2006).Crossref, Medline, CAS, Google Scholar
24 Zigoneanu IG, Astete CE, Sabliov CM. Nanoparticles with entrapped alpha-tocopherol: synthesis, characterization, and controlled release. Nanotechnology 19(10), 105606 (2008).Crossref, Medline, Google Scholar
25 Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 82(1), 105–114 (2002).Crossref, Medline, CAS, Google Scholar
26 Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61(2), 158–171 (2009).Crossref, Medline, CAS, Google Scholar
27 Wang JJ, Zeng ZW, Xiao RZ et al. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomedicine 6, 765–774 (2011).Medline, CAS, Google Scholar
28 Loeschner K, Hadrup N, Qvortrup K et al. Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate. Part. Fibre Toxicol. 8, 18 (2011).Crossref, Medline, CAS, Google Scholar
29 Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Deliv. Rev. 50, S69–S89 (2001).Crossref, Medline, CAS, Google Scholar
30 Quini CC, Americo M, Cora LA et al. Employment of a noninvasive magnetic method for evaluation of gastrointestinal transit in rats. J. Biol. Eng. 6, 1–6 (2012).Crossref, Medline, Google Scholar
31 Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 52, 481–503 (2012).Crossref, Medline, CAS, Google Scholar
32 Hagens WI, Oomen AG, De Jong WH, Cassee FR, Sips AJ. What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul. Toxicol. Pharmacol. 49(3), 217–229 (2007).Crossref, Medline, CAS, Google Scholar
33 Markovsky E, Baabur-Cohen H, Eldar-Boock A et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J. Control. Release 161(2), 446–460 (2012).Crossref, Medline, CAS, Google Scholar
34 Kiriyama A, Iga K, Shibata N. Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery. Ther. Deliv. 4(10), 1261–1278 (2013).Link, CAS, Google Scholar
35 Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64(6), 557–570 (2012).Crossref, Medline, CAS, Google Scholar
36 Desesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol. 39(3), 209–228 (2001).Crossref, Medline, CAS, Google Scholar
37 Kararli TT. Gastrointestinal Absorption of Drugs. Crit. Rev. Ther. Drug 6(1), 39–86 (1989).Medline, CAS, Google Scholar
38 Roth WL, Freeman RA, Wilson AGE. A physiologically-based model for gastrointestinal absorption and excretion of chemicals carried by lipids. Risk Anal. 13(5), 531–543 (1993).Crossref, Medline, CAS, Google Scholar
39 Baati T, Bourasset F, Gharbi N et al. The prolongation of the lifespan of rats by repeated oral administration of [60] fullerene. Biomaterials 33(19), 4936–4946 (2012).Crossref, Medline, CAS, Google Scholar
40 Steiniger B. Spleen. In: Encyclopedia of Life Sciences. Wiley, NJ, USA (2006).Crossref, Google Scholar
41 Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 3(5), 703–717 (2008).Crossref, Medline, CAS, Google Scholar

Vol. 5, No. 11

Metrics

Downloaded 80 times

History

Published online 10 December 2014

Published in print November 2014

Information

Financial & competing interests disclosure

This work was supported by the Increasing Scientific Data on the Fate, Transport and Behavior of Engineered Nanomaterials in Selected Environmental and Biological Matrices funding program administered jointly by the Environmental Protection Agency, National Science Foundation, and US Department of Agriculture, EPA-G2010-STAR-N2 Food Matrices Award # 2010–05269. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download